peoplePerson
Daniel A. Haber
Co-discovered EGFR mutations in lung cancer and pioneered circulating tumour cell technology.
Directs the Mass General Cancer Center. His lab co-reported EGFR mutations predicting gefitinib response (2004) and developed the CTC-Chip and downstream circulating tumour cell biology.
Role
Director, Mass General Cancer Center; HHMI Investigator
Institution
Specialisms
Circulating tumour cellsEGFR mutationsCancer genetics
Profiles
| Title | Journal | Year |
|---|---|---|
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | New England Journal of Medicine | 2004 |
| Isolation of rare circulating tumour cells in cancer patients by microchip technology | Nature | 2007 |
Pages like this
not linked directly; found by shared links- PersonLecia V. Sequist
Shares Massachusetts General Hospital Cancer Center, EGFR, Non-small-cell lung cancer.
- PersonRyan B. Corcoran
Shares Massachusetts General Hospital Cancer Center, EGFR, Liquid biopsy (ctDNA).
- TrialLAURA
Shares EGFR, Non-small-cell lung cancer.
- PersonNatasha B. Leighl
- ProductDacomitinib
Shares EGFR, Non-small-cell lung cancer.
- PersonMatthew Meyerson
Shares EGFR, Non-small-cell lung cancer.
- PersonThomas J. Lynch Jr.
Shares EGFR, Non-small-cell lung cancer.
- IdeactDNA-guided dose holidays for lung cancer targeted therapy
Shares EGFR, Liquid biopsy (ctDNA), Non-small-cell lung cancer.